A nomogram developed from a retrospective study of 11,721 early-stage hepatocellular carcinoma (HCC) patients reveals significant survival benefits from neoadjuvant chemotherapy (NAC) for those classified as high-risk. The model predicts 3-, 5-, and 10-year cancer-specific survival rates based on clinical and demographic factors. Risk stratification effectively identifies patients who may benefit from NAC, supporting personalized treatment decisions, though the findings require external validation for broader application.
Journal Article by Xu S, Duan L (…) Ma L et 2 al. in J Gastrointest Cancer
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.